HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, reported a bigger-than-expected ...

December quarter earnings brought a mixed bag of surprises across sectors. While rural demand revival lifted consumer-driven ...

Sun Pharma's Q3 earnings may see a slight setback in margins, pressured by increased R&D expenses and a lower contribution from cancer drug Revlimid.

Net Sales at Rs 13,675.46 crore in December 2024 up 10.46% from Rs. 12,380.70 crore in December 2023. Quarterly Net Profit at ...

Sun Pharmaceutical Industries Ltd. closed 13.04% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Shares of Sun Pharmaceutical Industries Ltd. 524715 rallied 3.12% to 1,746.50 Indian rupees Thursday, on what proved to be an all-around grim trading session for the stock market, with the BSE SENSEX ...

Sun Pharma's US formulation sales stood at $474 million during the quarter, which was lower than the expectations of $516 ...

The drug major will appeal against the order. Shares of Sun Pharmaceutical Industries Ltd ended at ₹1,762.90, up by ₹22.95, ...

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company ...

Sun Pharmaceutical Industries Ltd. reported consolidated net profit rose 15% to ₹2,903 crore for the third quarter ended December 31, 2024 from ₹2,524 crore a year earlier. Gross sales during the ...

Revenue from operations grew 10.5% yoy to ₹13,675.4 crore, compared with ₹12,381 crore registered for the same period in Q3 FY24 ...

Sales in India, Sun Pharma's largest revenue-generating region, rose 14% to 43 billion rupees, or about 31% of total sales. That was bigger than the 11% increase in the previous quarter.